Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab (MabCampath) plus 2-weekly CHOP for mature T-cell non-Hodgkin lymphoma
ISRCTN52265296Phase 2Completed
- Sponsor
- HOVON
- Start
- Nov 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab, cyclophosphamide, doxorubicin, vincristine, prednisone and 1 more in peripheral T-cell lymphoma (PTCL), sponsored by HOVON. Primary endpoint: Complete response including complete response uncertain on protocol. Started Nov 2005; status: completed.
02
Drugs
alemtuzumabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ISRCTN52265296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52265296.